HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia AML.

HanxBio has published a research paper titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the journal Scientific Reports. The paper describes the preclinical evaluation of Narazaciclib (HX301) for the treatment of acute myeloid leukemia (AML). The researchers conducted comprehensive pharmacology characterization of HX301 using various preclinical experimental AML models, demonstrating its strong anti-leukemia activity and potential mechanisms of action. The study also investigated the pharmacodynamics and pharmacokinetics of HX301, providing valuable information for clinical dosage selection. The results of this study will guide the clinical development strategies for HX301 in the treatment of AML. [Extracted from the article]